{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:24:28Z","timestamp":1786944268335,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary mucormycosis is a life-threatening invasive fungal infection, most often affecting immunocompromised patients. Liposomal amphotericin B is the preferred first-line therapy, but amphotericin B formulations may be poorly tolerated. When endobronchial obstruction and tissue necrosis are present, pulmonary lesions may progress despite systemic antifungal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed patients with documented pulmonary mucormycosis who received posaconazole-based therapy at the First Affiliated Hospital, Zhejiang University School of Medicine between May 2019 and December 2022. Patients who showed clinical deterioration, radiologic progression, or no meaningful radiologic improvement during posaconazole-based therapy and then underwent bronchoscopic airway clearance followed by local instillation of amphotericin B deoxycholate were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen patients received posaconazole-based antifungal therapy during the study period, and five met the eligibility criteria. Their mean age was 56.2 \u00b1 3.96 years; four had major underlying conditions, including hematologic malignancy or destroyed lung after tuberculosis, and one had a previous history of pulmonary and sinonasal fungal disease. Diagnostic evidence included mNGS, fungal fluorescence staining, bronchoalveolar lavage findings, and\/or histopathology. Bronchoscopy identified obstructing mucus plugs, purulent secretions, necrotic material, or segmental narrowing in all patients. Amphotericin B deoxycholate was locally instilled at 7.5\u201315 mg in 10\u201315 ml diluent for 2\u20133 sessions while posaconazole was continued. No treatment-limiting cough, clinically significant oxygen desaturation, hemoptysis, bronchospasm, or new hepatic or renal dysfunction related to the local procedure was documented. Follow-up CT showed partial absorption or shrinkage of the dominant pulmonary lesions in all five patients, and none required surgical resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this small retrospective case series, bronchoscopic airway clearance plus local instillation of amphotericin B deoxycholate appeared feasible and well tolerated as an adjunctive salvage approach for selected patients with pulmonary mucormycosis and inadequate response to posaconazole. Because mechanical clearance and local drug delivery were inseparable in this study, the efficacy of local amphotericin B cannot be established from these data alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1840224","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:32:49Z","timestamp":1786941169000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bronchoscopic local instillation of amphotericin B deoxycholate as adjunctive therapy for pulmonary mucormycosis with inadequate response to posaconazole: a retrospective case series"],"prefix":"10.3389","volume":"13","author":[{"given":"Liyan","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Quzhou Traditional Chinese Medicine Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyue","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Quzhou Traditional Chinese Medicine Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/ijd.ijd_477_21","article-title":"Mucormycosis: the scathing invader","volume":"66","author":"Vasudevan","year":"2021","journal-title":"Indian J Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1925362120960918","article-title":"The postmortem features of mucormycosis","volume":"10","author":"Halvorson","year":"2020","journal-title":"Acad Forensic Pathol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11046-021-00607-4","article-title":"Mucormycosis in mainland China: a systematic review of case reports","volume":"187","author":"Wei","year":"2022","journal-title":"Mycopathologia."},{"key":"B4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/s-0039-3401992","volume":"41","author":"Reid","year":"2020","journal-title":"Mucormycosis Semin. Respir Crit Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s15010-017-0991-6","article-title":"Pulmonary mucormycosis: clinical features and outcomes","volume":"45","author":"Lin","year":"2017","journal-title":"Infection."},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi (Basel)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s15010-018-1149-x","article-title":"Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome","volume":"46","author":"Feng","year":"2018","journal-title":"Infection."},{"key":"B8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/diseases8030032","article-title":"Pulmonary infectious complications in children with hematologic malignancies and chemotherapy-induced neutropenia","volume":"8","author":"Voulgaridou","year":"2020","journal-title":"Diseases."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.21037\/jtd.2019.12.53","article-title":"Clinical features of pulmonary mucormycosis in patients with different immune status","volume":"11","author":"Peng","year":"2019","journal-title":"J Thorac Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: recommendations, latest advances, and perspectives","volume":"30","author":"Brunet","year":"2020","journal-title":"J Mycol Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1055\/s-0041-1735383","article-title":"COVID-19-associated mucormycosis, a new incident in recent time: is an emerging disease in the near future impending?","volume":"11","author":"Ray","year":"2021","journal-title":"Avicenna J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada","year":"2018","journal-title":"Med Mycol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/myc.13092","article-title":"Risk factors for mortality in patients with pulmonary mucormycosis","volume":"63","author":"Son","year":"2020","journal-title":"Mycoses."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1111\/jam.15487","article-title":"Mucormycosis: the hidden and forgotten disease","volume":"132","author":"Darwish","year":"2022","journal-title":"J Appl Microbiol."},{"key":"B15","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S1473-3099(22)00124-4","article-title":"Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: delphi consensus statement from the fungal infection study forum and academy of pulmonary sciences, India","volume":"22","author":"Muthu","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/jcpt.13643","article-title":"Treatment and economic burden of mucormycosis in China: case report review and burden estimation","volume":"47","author":"Jian","year":"2022","journal-title":"J Clin Pharm Ther."},{"key":"B18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.riam.2021.04.003","article-title":"Mucormycosis: current and future management perspective","volume":"38","author":"Martin Gomez","year":"2021","journal-title":"Rev Iberoam Micol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/jamp.2022.0003","article-title":"Preclinical studies of the nebulized delivery of liposomal amphotericin B","volume":"35","author":"Kothari","year":"2022","journal-title":"J Aerosol Med Pulm Drug Deliv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/jof8020212","article-title":"Conventional antifungals for invasive infections delivered by unconventional methods: aerosols, irrigants, directed injections and impregnated cement","volume":"8","author":"Drew","year":"2022","journal-title":"J Fungi (Basel)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/IOP.0000000000000377","article-title":"Intraorbital irrigation of amphotericin B in the treatment of rhino-orbital mucormycosis","volume":"33","author":"Joos","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.riam.2021.02.001","article-title":"Clinical safety of liposomal amphotericin B","volume":"38","author":"Suberviola","year":"2021","journal-title":"Rev Iberoam Micol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/jac\/dkac351","article-title":"Liposomal amphotericin B-the past","volume":"77","author":"Bruggemann","year":"2022","journal-title":"J Antimicrob Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2547","DOI":"10.7759\/cureus.2547","article-title":"Isavuconazole: a promising salvage therapy for invasive mucormycosis","volume":"10","author":"Shafiq","year":"2018","journal-title":"Cureus."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s12070-021-02838-9","article-title":"Adverse drug reaction of antifungals in the management of black fungus: a tertiary care centre experience","volume":"74","author":"Sachdeva","year":"2022","journal-title":"Indian J Otolaryngol Head Neck Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/ICL.0000000000000723","article-title":"Combined intrastromal voriconazole and amphotericin B treatment for persistent fungal keratitis","volume":"46","author":"Aydin","year":"2020","journal-title":"Eye Contact Lens."},{"key":"B28","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/jac\/dkx440","article-title":"Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations","volume":"73","author":"Jeong","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/1060028016655425","article-title":"Breaking the mold: a review of mucormycosis and current pharmacological treatment options","volume":"50","author":"Riley","year":"2016","journal-title":"Ann Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/myc.13420","article-title":"Therapeutic drug monitoring of posaconazole delayed-release tablet while managing COVID-19-associated mucormycosis in a real-life setting","volume":"65","author":"Patel","year":"2022","journal-title":"Mycoses."},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5863\/1551-6776-25.1.47","article-title":"Comparison of the efficacy of posaconazole delayed-release tablets and suspension in pediatric hematology\/oncology patients","volume":"25","author":"Wass","year":"2020","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.mycmed.2017.11.003","article-title":"Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: a retrospective study","volume":"28","author":"Tang","year":"2018","journal-title":"J Mycol Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/myc.13028","article-title":"High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections","volume":"63","author":"Schauwvlieghe","year":"2020","journal-title":"Mycoses."},{"key":"B34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.riam.2018.07.008","article-title":"Successful posaconazole salvage therapy for rhinocerebral mucormycosis in a child with leukemia: review of the literature","volume":"36","author":"Ojeda-Diezbarroso","year":"2019","journal-title":"Rev Iberoam Micol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17476348.2017.1325322","article-title":"Combination therapy for the treatment of pulmonary mold infections","volume":"11","author":"McCarthy","year":"2017","journal-title":"Expert Rev Respir Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1840224\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:33:00Z","timestamp":1786941180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1840224\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":35,"alternative-id":["10.3389\/fmed.2026.1840224"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1840224","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1840224"}}